Association between the level of specific urinary SERPINA1 protein in pregnant women and the severity of preeclampsia and perinatal outcomes


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim: The study was aimed to identify association between SERPINA1/a1-antitrypsin (A1AT) and the severity of preeclampsia and perinatal/neonatal outcomes. Materials and methods: The analysis of medical histories, specific features of the course of pregnancy in 79 women, childbirth, postpartum period, and the state of health of their newborns was performed. Urine samples for testing were collected before 34 weeks of gestation, when pregnant women were admitted to hospital. All patients were divided into 3 groups: group 1 (the main group) included 41 pregnant women with preeclampsia; group 2 (the comparison group) - 17 women with chronic arterial hypertension; group 3 (the comparison group) - 18 women with normal pregnancy. Depending on the detected level of urinary SERPINA1 in pregnant women, group 1 was divided into 2 subgroups: 1a (n=23) - preeclampsia, SERPINA1 positive (PE SER+) and 1b (n=21) - preeclampsia, SERPINA1 negative (PE SER-). Results: The study confirmed the adverse effect of preeclampsia on the condition of the fetus and newborn. It was demonstrated, that determination of peptides of SERPINA1 (α1-antitrypsin) in the urine of pregnant women predicts a severe course of preeclampsia and was associated with a high incidence of growth retardation and fetal hypoxia. In infants born to women preeclampsia, SERPINA1 positive, there was a negative correlation with the body weight, Apgar score and necessity for resuscitation, as well as the duration of the newborn's stay in hospital. Conclusion: The study of the urine peptide profile - determination of SERPINA1 peptides contributes to the differential diagnosis of the severity of preeclampsia and other hypertension disorders during pregnancy helping to determine obstetric tactics and prognostically significant risk factors for the newborns.

Full Text

Restricted Access

About the authors

Anna L. Karavaeva

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology Ministry of Health of Russia

Email: a_karavaeva@oparina4.ru
doctor 117997, Russia, Moscow, Ac. Oparina str., 4

Victor V. Zubkov

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology Ministry of Health of Russia

Email: v_zubkov@oparina4.ru
PhD, Director of the Institute of Neonatology 117997, Russia, Moscow, Ac. Oparina str., 4

Nataliya L. Starodubtseva

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology Ministry of Health of Russia

Email: n_starodubtseva@oparina4.ru6
PhD, Head of the Laboratory of human reproduction proteomics 117997, Russia, Moscow, Ac. Oparina str., 4

Leila A. Timofeeva

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology Ministry of Health of Russia

Email: l_timofeeva@oparina4.ru
PhD, Head of the Neonatal Unit 117997, Russia, Moscow, Ac. Oparina str., 4

Natalia E. Kan

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology Ministry of Health of Russia

Email: kan-med@mailru
MD, PhD, Professor, Deputy Director of Science 117997, Russia, Moscow, Ac. Oparina str., 4

Victor L. Tyutyunnik

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology Ministry of Health of Russia

Email: tioutiounnik@mail.ru
MD, PhD, Professor, Leading Researcher of Research and Development Service 117997, Russia, Moscow, Ac. Oparina str., 4

Oleg R. Baev

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology Ministry of Health of Russia

Email: o_baev@oparina4ru
MD, PhD, Professor, Head of the Maternity Department, Head of the Department of Obstetrics and Gynecology 117997, Russia, Moscow, Ac. Oparina str., 4

Natalia V. Nizyaeva

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology Ministry of Health of Russia

Email: niziaeva@gmail.com
PhD, Head of the Pathoanatomical Department 117997, Russia, Moscow, Ac. Oparina str., 4

References

  1. Hutcheon J, Lisonkova S., Joseph K. Epidemiology of preeclampsia and the other hypertensive disorders of pregnancy. Best Pract. Res. Clin. Obstet. Gynaecol. 2011; 25(4): 391-403. https://dx.doi.org/10.1016/j.bpobgyn.2011.01.006.
  2. Mhiri R., Mvogo A., Kamga A., Yassinguezo S., Fagla H., Dotou D., Kallel H. Epidemiology and maternal prognosis of hypertension disorders of pregnancy in French Guiana. Pregnancy Hypertens. 2020; 20: 96-101. https://dx.doi.org/10.1016/j.preghy.2020.03.010.
  3. WHO recommendations for prevention and treatment of preeclampsia and eclampsia. WHO; 2011.
  4. Гипертензивные расстройства во время беременности, в родах и послеродовом периоде. Преэклампсия. Эклампсия: Федеральные клинические рекомендации (протокол лечения). М.; 2016. 72с.
  5. Pare E., Parry S., McElrath T.F., Pucci D., Newton A., Lim K.H. Clinical risk factors for preeclampsia in the 21st century. Obstet. Gynecol. 2014; 124(4): 763-70. https://dx.doi.org/10.1097/AOG.0000000000000451.
  6. Serrano-Perez B., Almeria S., Mur-Novales R., Lopez-Helguera I., Garcia-Ispierto I., Alabart J.L. et al. Uterine serpin (SERPINA 14) correlates negatively with cytokine production at the foetal-maternal interface but not in the corpus luteum in pregnant dairy heifers experimentally infected with Neospora caninum. Reprod. Domest. Anim. 2018; 53(2): 556-8. https://dx.doi.org/10.1111/rda.12937.
  7. Starodubtseva N., Nizyaeva N., Baev O., Bugrova A., Gapaeva M., Muminova K., Kononikhin A., Frankevich V., Nikolaev E., Sukhikh G. SERPINA1 peptides in urine as a potential marker of preeclampsia severity. Int. J. Mol. Sci. 2020; 21(3): 914. https://dx.doi.org/10.3390/ijms21030914.
  8. Law K.P., Han T.-L., Tong C., Baker P.N. Mass spectrometry-based proteomics for preeclampsia and preterm birth. Int. J. Mol. Sci. 2015; 16(5): 10952-85. https://dx.doi.org/10.3390/ijms160510952.
  9. Guo H.X., Zhu Y.B., Wu C.P., Zhong M., Hu S.W. Potential urine biomarkers for gestational hypertension and preeclampsia. Mol. Med. Rep. 2019; 19(4): 2463-70. https://dx.doi.org/10.3892/mmr.2019.9911.
  10. Buhimschi I.A., Zhao G., Funai E.F., Harris N., Sasson I., Bernstein I. et al. Proteomic profiling of urine identifies specific fragments of serpina-1. Am. J. Obstet. Gynecol. 2009; 199(5):551. e1-16. https://dx.doi.org/10.1016/j.ajog.2008.07.006.
  11. Стародубцева Н.Л., Бугрова А.Е., Кононихин А. С., Вавина О.В., Широкова В.А., Наумов В.А., Гаранина И.А., Лагутин В.В., Попов И.А., Логинова Н.С., Ходжаева З.С., Франкевич В.Е., Николаев Е.Н., Сухих Г.Т. Возможность прогнозирования и ранней диагностики преэклампсии по пептидному профилю мочи. Акушерство и гинекология. 2015; 6: 46-52.
  12. Rana S., Lemoine E., Granger J., Karumanchi S.A. Preeclampsia: pathophysiology, challenges, and perspectives. Circ. Res. 2019; 124(7): 1094-112. https://dx.doi.org/10.1161/CIRCRESAHA.118.313276.
  13. Parikh N.I., Gonzalez J. Preeclampsia and hypertension: courting a long while: time to make it official. JAMA Intern. Med. 2017; 177(7): 917-8. https://dx.doi.org/10.1001/jamainternmed.2017.1422.
  14. Ton T.G., Bennett M., Incerti D., Peneva D., Druzin M., Stevens W. et al. Maternal and infant adverse outcomes associated with mild and severe preeclampsia during the first year after delivery in the United States. Am. J. Perinatol. 2020; 37(4): 398-408. https://dx.doi.org/10.1055/s-0039-1679916.
  15. Backes C.H., Markham K., Moore he ad P., Cordero L., Nankervis C.A., Giannone P.J. Maternal preeclampsia and neonatal outcomes. J. Pregnancy. 2011; 2011: 214365. https://dx.doi.org/10.1155/2011/214365.
  16. Серов В.Н., Кан Н.Е., Тютюнник В.Л. Прогностическое значение отношения растворимой fms-подобной тирозинкиназы-1 к плацентарному фактору роста у беременных с преэклампсией. Акушерство и гинекология. 2016; 6: 5-10.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies